Statins do not prevent acute organ failure in ventilated ICU patients: Single-centre retrospective cohort study

Critical Care

Volumn 15, Issue 1, 2011, Pages

  Terblanche, Marius J ^a,b   Pinto, Ruxandra ^c   Whiteley, Craig ^b   Brett, Stephen ^d   Beale, Richard ^a,b   Adhikari, Neill K J ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; STATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BILIRUBIN BLOOD LEVEL; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPOTHESIS; INTENSIVE CARE UNIT; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; ORGAN INJURY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGERY; VENTILATED PATIENT; AGED; INTENSIVE CARE; LIVER DISEASE; METHODOLOGY; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; CRITICAL CARE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTENSIVE CARE UNITS; LINEAR MODELS; LIVER DISEASES; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79952047453     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10063     Document Type: Article

References (25)

1. Alberti C, Brun-Buisson C, Chevret S, Antonelli M, Goodman SV, Martin C, Moreno R, Ochagavia AR, Palazzo M, Werdan K, Le Gall JR. Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit Care Med 2005, 171:461-468. 10.1164/rccm.200403-324OC, 15531752.
2. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995, 273:117-123. 10.1001/jama.273.2.117, 7799491.
3. Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med 2000, 26(Suppl 1):S64-S74. 10.1007/s001340051121, 10786961.
4. Alberti C, Brun-Buisson C, Goodman SV, Guidici D, Granton J, Moreno R, Smithies M, Thomas O, Artigas A, Le Gall JR. Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. Am J Respir Crit Care Med 2003, 168:77-84. 10.1164/rccm.200208-785OC, 12702548.
5. Natanson C, Esposito CJ, Banks SM. The sirens' songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 1998, 26:1927-1931. 10.1097/00003246-199812000-00001, 9875887.
6. Shyamsundar M, McKeown ST, O'Kane CM, Craig TR, Brown V, Thickett DR, Matthay MA, Taggart CC, Backman JT, Elborn JS, McAuley DF. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 2009, 179:1107-1114. 10.1164/rccm.200810-1584OC, 2695496, 19324974.
7. Novack V, Eisinger M, Frenkel A, Terblanche M, Adhikari NK, Douvdevani A, Amichay D, Almog Y. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med 2009, 35:1255-1260. 10.1007/s00134-009-1429-0, 19205663.
8. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins: panacea for sepsis?. Lancet Infect Dis 2006, 6:242-248. 10.1016/S1473-3099(06)70439-X, 16554249.
9. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007, 7:358-368. 10.1016/S1473-3099(07)70111-1, 17448939.
10. Terblanche M, Smith TS, Adhikari NK. Statins, bugs and prophylaxis: intriguing possibilities. Crit Care 2006, 10:168. 10.1186/cc5056, 1751082, 17094793.
11. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 2008, 61:774-785. 10.1093/jac/dkn019, 18263570.
12. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, Ibrahim T. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009, 169:1658-1667. 10.1001/archinternmed.2009.286, 19822822.
13. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006, 97:52C-60C. 10.1016/j.amjcard.2005.12.010, 16581329.
14. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710. 10.1007/BF01709751, 8844239.
15. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
16. Fernandez R, De Pedro VJ, Artigas A. Statin therapy prior to ICU admission: protection against infection or a severity marker?. Intensive Care Med 2005, 32:160-164. 10.1007/s00134-005-2743-9, 16086178.
17. Schmidt H, Hennen R, Keller A, Russ M, Muller-Werdan U, Werdan K, Buerke M. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med 2006, 32:1248-1251. 10.1007/s00134-006-0246-y, 16788803.
18. Dobesh PP, Klepser DG, McGuire TR, Morgan CW, Olsen KM. Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy 2009, 29:621-630. 10.1592/phco.29.6.621, 19476415.
19. de Saint Martin L, Tande D, Goetghebeur D, Pan-Lamande M, Segalen Y, Pasquier E. Statin use does not affect the outcome of acute infection: a prospective cohort study. Presse Med 2010, 39:e52-e57. 10.1016/j.lpm.2009.09.022, 20022215.
20. Kor DJ, Iscimen R, Yilmaz M, Brown MJ, Brown DR, Gajic O. Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury. Intensive Care Med 2009, 35:1039-1046. 10.1007/s00134-009-1421-8, 19183945.
21. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002, 105:1446-1452. 10.1161/01.CIR.0000012530.68333.C8, 11914253.
22. Kruger PS, Harward ML, Jones MA, Joyce CJ, Kostner KM, Roberts MS, Venkatesh B. Continuation of statin therapy in patients with presumed infection: a randomised controlled trial. Am J Respir Crit Care Med 2011, 183:774-781.
23. Kruger PS, Freir NM, Venkatesh B, Robertson TA, Roberts MS, Jones M. A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med 2009, 35:717-721. 10.1007/s00134-008-1358-3, 19034423.
24. Shintani AK, Girard TD, Eden SK, Arbogast PG, Moons KG, Ely EW. Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies. Crit Care Med 2009, 37:2939-2945. 10.1097/CCM.0b013e3181b7fbbb, 19770737.
25. Craig TR, Duffy MJ, Shyamsundar M, McDowell C, C OK, Elborn JS, McAuley DF. A randomized clinical trial of hydroxymethylglutaryl-CoA reductase inhibition for acute lung injury (the HARP study). Am J Respir Crit Care Med 2011, 183:620-626.